Metagenomic sequencing has emerged as a tool for the diagnosis of infectious diseases. It can be performed on cerebrospinal fluid to help detect and identify causes of encephalitis and meningitis and has expanded diagnostic capabilities beyond those provided by traditional methods. Given its ability to analyze genetic material from an array of microorganisms, including viruses, bacteria, parasites, and fungi, metagenomic sequencing can provide a comprehensive approach to identifying infectious agents.
This webinar will cover metagenomic sequencing for diagnosing central nervous system infection. Content will be shared regarding technical details, clinical applications, and results interpretation.
Robin Patel, M.D.
Director, Infectious Diseases Research Laboratory
Co-Director, Bacteriology Laboratory
Consultant, Divisions of Clinical Microbiology and Infectious Diseases
Mayo Clinic
Rochester, Minnesota
Upon completion of this activity, participants should be able to:
This webinar is appropriate for microbiologists, infectious disease specialists, laboratory directors, lab supervisors, laboratory technicians, pathologists, and laboratory send-out coordinators/managers.
The following types of credit are offered for this event:
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Microbiology/Mycology/Parasitology) credit. This program has been approved for 1.0 contact hour.
1. Watch the video.
2. Complete the posttest and evaluation that launches immediately following the video.
3. Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Credit for this recording expires on November 12, 2026.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: mcleducation@mayo.edu